Feature | April 08, 2014

GE Healthcare Receives FDA for Q.Clear PET/CT Technology

Technology can enable clinicians to assess patient's response to treatment accurately

GE Healthcare Q.Clear Technology PET/CT Systems Nuclear Imaging

April 8, 2014 — GE Healthcare received U.S. Food and Drug Administration (FDA) 510(k) clearance of its Q.Clear technology, which is designed to provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. 

Over the last decade, positron emission tomography (PET) image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as time of flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare said its Q.Clear technology brings convergence to PET imaging without the need for compromise between quantitation and image quality.

"Q.Clear is a major step forward because it can give us a consistent and reliable measurement when determining whether the current course of a patient's cancer treatment is effective," said Dr. Gustav von Schulthess, nuclear medicine chair at University Hospital Zurich. "It will give the oncologist more confidence because if a change of therapy is needed, you want accurate information early on to best adjust treatment for the patient."

Clinicians not only want the ability to detect smaller lesions, but the ability to determine earlier whether the patient is responding to current treatment. Q.Clear aims to help in both areas by providing better quantitation accuracy for truly personalized medicine. Coupled with Q.Suite, which introduced the importance of eliminating variability such as respiratory motion, Q.Clear can enable clinicians to assess treatment response accurately.

"We know that approximately 70 percent of cancer patients don't always respond to their initial course of treatment," said Steve Gray, president and CEO of GE Healthcare MICT. "If we can give clinicians an accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/computed tomography (CT) can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures.  Q.Clear gives clinicians the ability to help make that determination."

GE said the system may not be available for sale in all regions. For countries that require CE marking, Q.Clear is not yet CE marked.

For more information: www3.gehealthcare.com

Related Content

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals| February 07, 2017
GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has...
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging| January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
News | Radiopharmaceuticals and Tracers| January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging| January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging| January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| December 28, 2016
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmac
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
PET/CT, calcium blockages, heart attack risk, Intermountain study, American Heart Association, AHA Scientific Sessions 2016
News | PET-CT| November 15, 2016
Many people who experience chest pain but don’t have a heart attack breathe a big sigh of relief when a stress test...
PET/CT, atherosclerotic plaque detection, Stanford University

Application of dual-modality optical and PET/CT activity-based probe in experimental carotid inflammation model. Coronal noninvasive PET/CT scans of (A) healthy and (B) diseased mice with and without ligated carotid arteries respectively. Inset images show optical ex vivo florescence imagining of (A) healthy and (B) diseased carotid arteries.  PET/CT and optical images courtesy of Xiaowei Ma, Toshinobu Saito and Nimali Withana.

News | PET-CT| November 01, 2016
Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission...
Overlay Init